Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
IGM Biosciences Inc (NASDAQ: IGMS) closed the day trading at $1.71 down -3.66% from the previous closing price of $1.77. In other words, the price has decreased by -$3.66 from its previous closing price. On the day, 0.87 million shares were traded. IGMS stock price reached its highest trading level at $1.81 during the session, while it also had its lowest trading level at $1.6501.
Ratios:
For a better understanding of IGMS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.22 and its Current Ratio is at 5.22. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on January 10, 2025, Downgraded its rating to Hold and sets its target price to $2.50 from $27 previously.
On January 10, 2025, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $20 to $1.50.
Morgan Stanley Downgraded its Equal-Weight to Underweight on January 10, 2025, whereas the target price for the stock was revised from $12 to $2.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 16 ’24 when Weber Steven sold 539 shares for $7.48 per share. The transaction valued at 4,032 led to the insider holds 31,704 shares of the business.
Decker Lisa Lynn sold 1,063 shares of IGMS for $7,951 on Dec 16 ’24. The CHIEF BUSINESS OFFICER now owns 78,041 shares after completing the transaction at $7.48 per share. On Dec 16 ’24, another insider, Harler Mary Beth, who serves as the Chief Executive Officer of the company, sold 1,708 shares for $7.48 each. As a result, the insider received 12,776 and left with 347,032 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGMS now has a Market Capitalization of 101683784 and an Enterprise Value of -71246248. For the stock, the TTM Price-to-Sale (P/S) ratio is 34.82 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at -24.416 whereas that against EBITDA is 0.318.
Stock Price History:
The Beta on a monthly basis for IGMS is 0.17, which has changed by -0.82124877 over the last 52 weeks, in comparison to a change of 0.23147523 over the same period for the S&P500. Over the past 52 weeks, IGMS has reached a high of $22.50, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is -81.19%, while the 200-Day Moving Average is calculated to be -83.30%.
Shares Statistics:
Over the past 3-months, IGMS traded about 346.67K shares per day on average, while over the past 10 days, IGMS traded about 946310 shares per day. A total of 34.06M shares are outstanding, with a floating share count of 17.58M. Insiders hold about 70.43% of the company’s shares, while institutions hold 30.68% stake in the company. Shares short for IGMS as of 1735603200 were 2511803 with a Short Ratio of 7.25, compared to 1732838400 on 2703497. Therefore, it implies a Short% of Shares Outstanding of 2511803 and a Short% of Float of 16.510001.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of IGM Biosciences Inc (IGMS) in the stock market.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.43 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$3.26 and -$3.62 for the fiscal current year, implying an average EPS of -$3.38. EPS for the following year is -$1.54, with 6.0 analysts recommending between -$0.72 and -$3.56.
Revenue Estimates
For the next quarter, 9 analysts are estimating revenue of $2.49M. There is a high estimate of $5.91M for the next quarter, whereas the lowest estimate is $750k.
A total of 10 analysts have provided revenue estimates for IGMS’s current fiscal year. The highest revenue estimate was $3.27M, while the lowest revenue estimate was $2.27M, resulting in an average revenue estimate of $2.63M. In the same quarter a year ago, actual revenue was $2.13M
